BD reveals $5.27 billion Q4 revenue, raises 2027 outlook

Becton, Dickinson and Company (NYSE:BDX) reported fiscal fourth-quarter 2026 revenue of $5.274 billion, up 5.4% year over year, while adjusted diluted earnings per share increased 27.3% to $4.15.

Revenue increased from $5.005 billion in the prior-year quarter, while fourth-quarter adjusted EPS exceeded analyst estimates of approximately $4.06–$4.07 per share.

GAAP diluted EPS from continuing operations increased 110% to $2.52 from $1.20, while operating income rose 92.5% to $1.032 billion from $536 million.

Full-year revenue reached $19.457 billion, up 4.9%, and adjusted EPS was $12.70.

BD forecast fiscal 2027 adjusted diluted EPS of $13.10–$13.30 and low-single-digit revenue growth, while full-year 2026 cash from continuing operations increased 30% to $3.605 billion and free cash flow rose 42.5% to $2.933 billion.

BD develops medical technology products and services across medical essentials, connected care, biopharma systems and interventional healthcare, supplying hospitals, laboratories, pharmaceutical manufacturers and other healthcare providers worldwide.

The company is focusing on its post-separation medical technology business, improving manufacturing productivity and expanding domestic production.

BD also announced plans to invest $19 billion in the United States over several years, including $3 billion for manufacturing expansion.